References

Abstract | Methods | Results | Discussion | Conclusions | References

A Strategy to Arrest and Reverse Coronary Artery Disease: A 5-Year Longitudinal Study of a Single Physician’s Practice
Caldwell B. Esselstyn, Jr, MD; Stephen G. Ellis, MD; Sharon V. Medendorp, MPH; and Timothy D. Crowe

1. Kesreloot H, Huang DX, Yang XS, Claes J, Rosseneu M, Geboers J, er al. Serum lipids in the People’s Republic of China. Comparison of Western and Eastern populations. Arteriosclerosis 1985; 5:427–33.
2 Wissler RW, Vesselinovitch D. Atherosclerosis in non-human primates. Adv Vet Sci Comp Mcd 1977; 21:351–420.
3. Kane JP, Malloy MI, Ports TA, Phillips NR, Dichl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007–12.
4. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill I,. Beneficial effects of combined colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233–40.
5. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, er al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men ~with high levels of apolipoprotein B. N EngI J Mcd 1990; 323:1289–98.
6. Ornish 1), Brown SE, Scherwitz LW, Billings JH, Armstrong ‘NT, Ports TA, er al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129–33.
7. Watts GE, Lewis B, Brunt IN, Lewis ES, Coltart DI, Smith LD, et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study (STARS). t.ancer 1992; 339:563–9.
8. Blankenhorn DH, Azen SF, Kramsch DM, Mack ‘NJ, Cashin Hemphill L, Hodis HN, Ct al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993; 119:969–76.
9. Arntzenius AC, Kromhotit D, Barth JD, Reiber JH, Bruschke AV, Buis B, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N EngI J Med 1985; 3 12:805–11.
10. Buchwald H, Varco RE, Marts IP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N EngI J Med 1990; 323:946–55.
11. Blankenhorn D, Johnson RI., Mack WJ, el Zein HA, Vailas LI. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 1990; 263:1646–52.
12. Hambrecht R, Niebauer I, Marburger C, Grunze M, Kalberer B, Hatier K, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol 1993; 22 :468–77.
13. Oliver MF, de Fevter PJ, Ltibscn II, Pocock 5, Simoons M, for the MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancer 1994; 344: 633–8.
14. Haskell WL, Alderman EL, Fair JM, Maron DI, Mackey SF, So perko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89:975–90.
15. Scandinavian Simyastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastarin Survival Study (4S). Lancer 1994; 344:1383–9.
16. Pritikin R. The new Pritikin program. New York, NY: Simon & Schuster, 199(1. 567
17. Temple NJ, Burkitt DP. Western Diseases–their dietary prevention and reversibility. Totowa, NJ: Humana, 1994.
18. McDougall IA, McDougall MA. The McDougall plan. Piscataway, NJ: New Century, 1983.
19. McDougall IA. McDougall’s medicine–a challenging second opinion. Piscatawav, NJ: New Century, 1985.
20. McDougall MA. The McDougall health-supporting cookbook– volumes 1 & 2. Piscataway, NJ: New Century, 1985, 1986.
21. Kurzweil R. The 10% solution for a healthy life. New York, NY: Crown, 1993.
22. Ornish D. Eat more, weigh less. New York, NY: HarperCollins, 1993.
23. Heart throb cookbook. Cleveland, Ohio: The Cleveland Clinic Foundation, 1995.
24. McDougall JA. Maximum weight loss. New York, NY: Dutton, 1994.
25. Campbell 5, Winant T. The healthy school lunch action guide. 2nd ed. Santa Fe, NM: Bear and Cu, 1994.
26. Schlesinger S. 500 fat free recipes.. New York: Villard Books, 1994.
27. Hurst JW. The heart, arteries and veins. 6th ed. New York, NY: McGraw-Hill, 1986.
28. Nutritionist III instruction manual. Version 7.0. Salem, Ore: N- Squared Computing, 1991.
29. Aldridge HF, Trimhle AS. Progression of proximal coronary artery lesions to total occlusion after aortocoronary saphenous vein by pass grafting. I Thorac Cardiovasc Surg 1971; 62(1):7–11.
30. Bousvaros G, Piracha AR, Chaudhry MA, Grant C, Older TM, Pifarre R. Increase in severity of proximal coronary disease after successful distal aortocoronary grafts–its nature and effects. Circulation 1972; 46:870–9.
31. Maurer BJ, Oberman A, Holt JH Jr, Kouchoukos NT, Jones WB, Russell RO Jr, et al. Changes in grafted and nongrafted coronary arteries following saphenous vein bypass grafting. Circulation 1974; 50:293–300.
32. Pasternak R, Cohn K, SeIzer A, Langston Mb Jr. Enhanced rate of progression of coronary artery disease following aorta-coronary saphenous vein bypass surgery. Am J Med 1975; 58:166–70.
33. Gould KL. Reversal of coronary atherosclerosis–clinical promise as the basis for noninvasive management of coronary artery disease. Circulation 1994; 90:1558–71.
34. Treasure CB, Klein JL, Weintratib WS, Talley JD, Stillahower ME Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on coronary endothelium in patients with coronary artery disease. N EngI J Med 1995; 332:481–7.
35. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N EngI J Med 1995; 332:488–93.
36. Levine GN, Keany JF It, Vita IA. Cholesterol reduction in cardio vascular disease. N EngI J Med 1995; 332:512–21.
37. Thompson SG, Kienast I, Pyke SD, Haverkare F, van de Loo JC, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and thc risk of myocardial infarction or sudden death in patients with angina pectoriss. N EngI I Med 1995; 332:635–41.
38. Roberts WC. Atherosclerotic risk factors–are there ten or is there only one? Am J Cardiol 1989; 64:552–4.
39. Mattes RD. Fat preference and adherence to a reduced-far diet. Am J Clin Nutr 1993; 57:373–81.
40. Hale JL, Dillard IP. Fear appeals in health promotion campaigns: too much, too little, or just right? In: Maihach E, Parrott RL, eds. Designing health messages. Approaches from communication theory and public health practice. Thousand Oaks, Calif: Sage Publications, 1995:65–80.
41. Gould KL. Invasive procedures in acute myocardial infarction. Are they beneficial? JAMA 1994; 272:891–3.

==============

Submitted, revised, August11, 1995.
From the Departments of General Surgery (UBE.), Cardioloqy (SUE., T.D.C9, and Biostatistics and Epidemiology (S. V.M.), The Cleveland Clinic Foundation, Cleveland, Ohio. Requesesfor reprints should be addressed to Caldirell B. Esselseyn, Jr., MD, Department of General Surgery, A80, The Cleveland Clinic Foundation, 9500 Euclid Are, Cleveland, OH 44195.

ARTICLE CONTINUED:
Abstract | Methods | Results | Discussion | Conclusions | References